Logo

Abbott’s Proclaim XR Spinal Cord Stimulation System Receives the US FDA’s Approval for Painful Diabetic Peripheral Neuropathy

Share this

Abbott’s Proclaim XR Spinal Cord Stimulation System Receives the US FDA’s Approval for Painful Diabetic Peripheral Neuropathy

Shots:

  • Abbott has gained US FDA approval for its Proclaim XR spinal cord stimulation system to treat painful diabetic peripheral neuropathy. The system offers alternative options for those patients receiving other medications
  • The system was originally approved in 2019 for treating chronic pain. It now offers DPN patients relief from chronic pain through low doses of stimulation & the battery lasts up to 10 years at low-dose settings
  • The system also pairs with Abbott’s NeuroSphere Virtual Clinic, a connected care app for people to communicate with a physician and receive remote treatment adjustments. In the clinical studies, SCS treatment led to a significant reduction in pain more effectively in lower limbs & improved QoL over conventional medical treatment alone

Ref: Abbott | Image: Abbott

Related Post; Abbott’s Eterna Spinal Cord Stimulation System Receives the US FDA’s Approval for the Treatment of Chronic Pain

Click here to­ read the full press release 

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions